FILTER
FILTERED INTERVIEW RESULTS
Michael Bigham & Evan Loh
PARATEK PHARMACEUTICALS
Paratek focuses on drugs that target infectious disease and other difficult-to-treat conditions.
Richard Peters
PRESIDENT AND CEO, MERRIMACK PHARMACEUTICALS
Merrimack Pharmaceuticals is focused on cancer treatment through a deeper understanding of cancer pathways and biological markers.
Ankit Mahadevia & Cristina Larkin
CEO & CHIEF COMMERCIAL OFFICER, SPERO THERAPEUTICS
Spero Therapeutics is developing new antimicrobial drugs to substitute those that have become ineffectual as they meeting resistance.
Travis McCready
PRESIDENT & CEO, MASSACHUSETTS LIFE SCIENCES CENTER
The Massachusetts Life Sciences Center has spent a billion dollars to ensure the best possible environment for the life sciences industry.
Robert K. Coughlin
PRESIDENT & CEO, MASSACHUSETTS BIOTECHNOLOGY COUNCIL
Founded in 1985, MassBio’s mission is to advance Massachusetts’ leadership in life sciences to grow the industry.
Naresh Raisinghani
CEO & EXECUTIVE DIRECTOR, BMGI INDIA
BMGI India offers expertise is improving efficiencies in strategy, innovation, problem solving and business transformation.
Akshay Singh
MANAGING DIRECTOR, SGD PHARMA INDIA
Cogent Glass, recently acquired by SGD Pharma, is a manufacturer of Type I moulded and tubular glass vials for the pharmaceutical industry.
Harish Shah
MANAGING DIRECTOR, SIGNET
Signet is India’s largest excipient company with extensive activities extending to Bangladesh and the Middle East.
Shri. KT Rama Rao
GOVERNMENT OF TELANGANA
Telangana State contains one of India’s most important life science clusters and its Government explains to GBR its plans to maintain the State’s rapid industrial growth.
Anil Jain
DIRECTOR, S.A. PHARMACHEM
S. A. Pharmachem is a specialty food and pharmaceutical manufacturing and marketing company supplying innovative specialty ingredients.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
